🇺🇸 FDA
Pipeline program

Ropidoxuridine

S22-11168

Phase 2 small_molecule terminated

Quick answer

Ropidoxuridine for Glioblastoma, IDH-wildtype is a Phase 2 program (small_molecule) at Shuttle Pharmaceuticals Holdings with 1 ClinicalTrials.gov record(s).

Program details

Company
Shuttle Pharmaceuticals Holdings
Indication
Glioblastoma, IDH-wildtype
Phase
Phase 2
Modality
small_molecule
Status
terminated

Clinical trials